Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Sep;25(9):2634-2646.
doi: 10.1007/s12094-023-03245-y. Epub 2023 Aug 4.

SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)

Pedro Pérez Segura  1 , Noelia Vilariño Quintela  2   3 , María Martínez García  4   5 , Sonia Del Barco Berrón  6 , Regina Gironés Sarrió  7 , Jesús García Gómez  8 , Almudena García Castaño  9 , Luis Miguel Navarro Martín  10 , Oscar Gallego Rubio  11 , Estela Pineda Losada  12
Affiliations

SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)

Pedro Pérez Segura et al. Clin Transl Oncol. 2023 Sep.

Abstract

High-grade gliomas (HGG) are the most common primary brain malignancies and account for more than half of all malignant primary brain tumors. The new 2021 WHO classification divides adult HGG into four subtypes: grade 3 oligodendroglioma (1p/19 codeleted, IDH-mutant); grade 3 IDH-mutant astrocytoma; grade 4 IDH-mutant astrocytoma, and grade 4 IDH wild-type glioblastoma (GB). Radiotherapy (RT) and chemotherapy (CTX) are the current standard of care for patients with newly diagnosed HGG. Several clinically relevant molecular markers that assist in diagnosis and prognosis have recently been identified. The treatment for recurrent high-grade gliomas is not well defined and decision-making is usually based on prior strategies, as well as several clinical and radiological factors. Whereas the prognosis for GB is grim (5-year survival rate of 5-10%) outcomes for the other high-grade gliomas are typically better, depending on the molecular features of the tumor. The presence of neurological deficits and seizures can significantly impact quality of life.

Keywords: Epidemiology; High-grade gliomas; Management; Molecular; Treatment.

PubMed Disclaimer

Conflict of interest statement

EP reports travel, hotel accomodation and registry to an european congress from Pfizer and Advisory Board from Novocure. MMG reports Advisory Board from Boehringer Ingelheim, Takeda, Seattle Genetics and Pierre Fabre; Other from Pfizer, Daiichi-Astra Zeneca and Gilead. PPS, NVQ, SdBB, RGS, JGG, AGC, LMNM, OGR have nothing to disclose.

References

    1. Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, et al. Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol. 2012;107(1):207–212. doi: 10.1007/s11060-011-0738-7. - DOI - PMC - PubMed
    1. Tran B, Rosenthal MA. Survival comparison between glioblastoma multiforme and other incurable cancers. J Clin Neurosci. 2010;17:417. doi: 10.1016/j.jocn.2009.09.004. - DOI - PubMed
    1. Fabbro-Peray P, Zouaoui S, Darlix A, Fabbro M, Pallud J, Rigau V, et al. Association of patterns of care, prognostic factors, and use of radiotherapy–temozolomide therapy with survival in patients with newly diagnosed glioblastoma: a French national population-based study. J Neurooncol. 2019;142(1):91–101. doi: 10.1007/s11060-018-03065-z. - DOI - PMC - PubMed
    1. Ostrom QT, Patil N, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2013–2017. Neuro Oncol. 2020;22(Supplement_1):IV1–96. doi: 10.1093/neuonc/noaa200. - DOI - PMC - PubMed
    1. Philips A, Henshaw DL, Lamburn G, O’Carroll MJ. Brain tumours: rise in glioblastoma multiforme incidence in England 1995–2015 Suggests an Adverse Environmental or Lifestyle Factor. J Environ Public Health. 2018 doi: 10.1155/2018/7910754. - DOI - PMC - PubMed